Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Outlook Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
OTLK
Nasdaq
8731
https://outlooktherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Outlook Therapeutics Inc
Outlook Therapeutics® to Present at the Retina World Congress 2024
- May 2nd, 2024 1:05 pm
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
- Apr 29th, 2024 1:00 pm
Marriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors
- Apr 26th, 2024 10:37 am
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
- Apr 15th, 2024 8:15 pm
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
- Apr 15th, 2024 4:54 pm
Insiders are Piling into These 10 Healthcare Stocks in 2024
- Apr 10th, 2024 7:30 pm
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
- Mar 22nd, 2024 11:35 am
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
- Mar 18th, 2024 9:10 pm
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
- Mar 12th, 2024 12:05 pm
7 of the Best Speculative Stocks You Can Snag for Less Than $1
- Mar 6th, 2024 8:36 pm
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
- Feb 25th, 2024 6:37 pm
Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments
- Feb 14th, 2024 10:27 pm
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
- Feb 14th, 2024 1:05 pm
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
- Jan 31st, 2024 1:05 pm
Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study
- Jan 24th, 2024 1:06 pm
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
- Jan 23rd, 2024 1:00 pm
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EU
- Dec 22nd, 2023 1:05 pm
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010
- Dec 19th, 2023 1:05 pm
Outlook Therapeutics® Announces Strategic Organizational Realignment
- Dec 6th, 2023 1:05 pm
Loss-Making Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected To Breakeven In The Medium-Term
- Nov 28th, 2023 11:02 am
Scroll